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Abstract
Patients suffering from adult acute lymphoblastic leukemia are acutely ill and present most
commonly with fever, pallor, bleeding, lymphadenopathy, hepatosplenomegaly and presence of
lymphoblasts in the peripheral blood and bone marrow. We describe a rare presentation of acute
lymphoblastic leukemia, in a young adult male who had vague and minimal symptoms with mild
splenomegaly. There was severe eosinophilia along with absence of blasts in the peripheral blood,
and 40% blasts with increase in eosinophils in the bone marrow. The blasts were positive for
common precursor B cell markers on flow cytometry. The patient had a unique cytogenetic
abnormality t(7;12)(q22;p13),-9, not previously described in acute lymphoblastic leukemia. He was
categorized as poor risk due to failure to achieve complete remission after induction with UK ALL
XII chemotherapy.
Introduction
Severe eosinophilia, defined as eosinophil count > 5000/
μl, can be seen in helminthic infections, allergic disorders,
lymphoproliferative disorders, chronic myeloid leukemia,
and chronic eosinophilic leukaemia[1]. A history of aller-
gic disorders, exposure to helminthic infestations, passage
of worms in feces, drug intake, weight loss, fever, cough,
diarrhoea and skin rash need to be complemented with
proper clinical examination to delineate the likely cause
of eosinophilia. Extensive investigations, which include
stool examination, chest X Ray, ultrasound abdomen, CT
scan, bone marrow aspiration/biopsy and cytogenetic
studies, are required to know the etiology and differenti-
ate between 'reactive' or 'clonal' eosinophilia.' Severe eosi-
nophilia may occur several years before the onset of
haematological malignancy, like in Hodgkin lym-
phoma[2], and may pose a diagnostic dilemma.
Precursor B acute lymphoblastic leukemia with exagger-
ated eosinophilia is a rare entity with less than 50 cases
reported since 1973, when it was first described by Spitzer
and Garson [3,4]. In most patients, the characteristic fea-
ture of ALL with eosinophilia is the absence of blasts in
the peripheral blood film. This could lead to delay in the
diagnosis, if bone marrow aspiration is not done and the
patient is started on steroid therapy. The most common
cytogenetic abnormality encountered in acute lymphob-
lastic leukemia with eosinophilia is t(5;14), and is charac-
terized by overproduction of IL-3 [5]. The latter entity is
now included as 'B lymphoblastic leukemia/lymphoma
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with t(5;14); IL3-IGH' in new WHO classification of lym-
phoid neoplasms published in 2008 [6].
In the following case report, diagnosis and management
of a young male is discussed who suffered from precursor
B acute lymphoblastic leukemia with severe eosinophilia,
and a unique cytogenetic abnormality
45,XY,t(7;12)(q22;p13),-9, reported for the first time.
Case Description
A 31 years old male presented with history of aches and
pains in whole body especially marked in temporoman-
dibular joints, lower legs and both hip joints lasting for 1
month. He was also suffering from fatigue and general-
ized weakness for the same duration. There was no history
of fever, allergies, skin rash, cough, urinary and bowel
complaints. He is employed in Navy as a marine, and is a
non-smoker, non-diabetic and non-hypertensive. He had
received anti-tuberculosis treatment 3 years ago for pul-
monary Koch's. At the time of his present illness, he was
not taking any medications. He was living in the sailors'
accommodation with his colleagues, and there was no
history of handling of any pets. Both his parents and his 5
siblings were healthy, and did not have history of major
illness in the past.
On physical examination he was comfortable, afebrile,
and did not have any bone tenderness. There was no pal-
lor, jaundice or lymphadenopathy. Pulse was 78/minute
and blood pressure was 110/75 mmHg. The heart and
lungs were normal on auscultation, and there were no
murmurs or added sounds. On abdominal examination
liver was not palpable, while spleen was enlarged and pal-
pable 3 cm below left costal margin. Neurological exami-
nation did not show any abnormality.
His complete blood counts showed Hb: 13.6 g/dl, total
leucocyte count 48 × 109/l with 72% eosinophils, 21%
neutrophils, 7% lymphocytes; and platelet count 167 ×
109/l. The absolute eosinophil count was 34.5 × 109/l
(34,560/cmm), and the eosinophils had heterogenous
morphology in peripheral blood film (Fig 1). His ultra-
sound abdomen revealed splenomegaly, while there was
no enlargement of para-aortic lymph nodes, or presence
of abdominal/pelvic mass and abscess. 2-D echocardiog-
raphy showed normal sized cardiac chambers with good
left ventricular contraction. There were no vegetations on
the valves, no left ventricular hypertrophy and ejection
fraction was >65%. Electrocardiography revealed sinus
rhythm and no evidence of any abnormality including
axis deviation, ischaemia, previous infarction or heart
block. Chest X-Ray showed normal lung fields and cardiac
shadow. Serum bilirubin, ALT, alkaline phosphatase,
urea, creatinine, sodium, potassium, uric acid and blood
glucose were within normal limits. Stool routine examina-
tion did not show any ova or cysts.
His bone marrow examination showed a hyperplastic
marrow with depressed erythropoiesis and reduced meg-
akaryocytes. Myelopoiesis showed increase in eosinophils
and their precursors. There was infiltration by 40% blasts
with high nucleo-cytoplasmic ratio, homogenous nuclear
chromatin pattern and a thin rim of light basophilic cyto-
plasm (Fig 2). The blasts were negative for Sudan Black B,
acid phosphatase but displayed occasional block positiv-
ity with Periodic Acid Schiff stain. Flow cytometric analy-
Increased eosinophils with heterogenous features in periph- eral blood film Figure 1
Increased eosinophils with heterogenous features in 
peripheral blood film.
Bone marrow aspirate of patient showing presence of blasts  with high nucleocytoplasmic ratio and eosinophilic precur- sors Figure 2
Bone marrow aspirate of patient showing presence 
of blasts with high nucleocytoplasmic ratio and eosi-
nophilic precursors.Journal of Hematology & Oncology 2009, 2:26 http://www.jhoonline.org/content/2/1/26
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sis (FC500 Beckman Coulter) was done after incubation
of bone marrow mononuclear cells with a panel of fluo-
rescence labeled antibodies (obtained from Becton Dick-
inson, USA). The blast cell population showed strong
reactivity (>95%) with B-cell markers including CD10,
CD19, CD20, CD22 and cCD79a.
The blasts did not show expression of lymphoid T markers
(CD3, 5 & 7) and myeloid markers (CD 13, 33 & cMPO).
HLA-DR and cTdT also showed strong positivity. There
were no detectable surface immunoglobulins or cytoplas-
mic light chains (IgM, IgG, kappa, lambda). The immu-
nophenotype was consistent with common precursor B-
lymphoblastic leukaemia. Cytogenetic analysis (Fig 3)
revealed karyotype 45 XY, t(7;12)(q22;p13),-9[15]/46,XY
[05]. Routine examination of cerebrospinal fluid showed
a protein level: 0.33 g/l, glucose: 4.4 mmol/l and occa-
sional mature lymphocytes on Leishman's stain (There
were no blasts seen in the cytospin smear).
The height and weight of the patient was 170 cm and 70
kg, respectively, and the body surface area was 1.7 m2. He
was started on induction therapy based on UK ALL XII
consisting of four drugs regimen, which included Inj vin-
cristine 1.5 mg/m2 IV on day 1, 8, 16 and 24; Inj daunoru-
bicin 60 mg/m2  IV on day 1, 8, 16 and 24; tab
prednisolone 60 mg/m2/day × 28 days and Inj asparagi-
nase 6000 units/m2 IM days 18, 19, 20, 21, 22, 23 and 24.
He was also given intrathecal methotrexate 12.5 mg on
days 1 and 8. The patient tolerated chemotherapy well,
except that he developed an episode of gastroenteritis on
12th day of chemotherapy. He was rehydrated with IV flu-
ids, and was administered Inj ciprofloxacin 400 mg b.d.
and Inj Metronidazole 500 mg IV 8 hourly. For pneumo-
cystis prophylaxis, he was given Co-trimoxazole 960 mg
b.d 3 times a week. On the 20th day of the induction ther-
apy, the complete blood counts showed correction of
eosinophilia with a total leucocyte count of 8.1 × 109/l
with 81% neutrophils, 12% lymphocytes, 05% eosi-
nophils and 02% monocytes; Hb: 11.7 g/dl and platelet
count: 170 × 109/l. His repeat bone marrow biopsy which
was done on the 28th day of induction therapy showed
active hematopoiesis with increase in eosinophil precur-
sors and presence of 10% blasts in the marrow. Biochem-
ical profile including serum urea, creatinine, electrolytes,
bilirubin, ALT and uric acid were within normal limits.
Serum LDH was 1254 U/ml (normal range: 250–500 u/
ml). Due to his partial response to chemotherapy, re-
induction therapy was given to him with the following
drug combination: Inj vincristine 1.5 mg/m2 day 1, Inj
daunorubicin 45 mg/m2 days 1 & 2; Inj etoposide 100
mg/m2 days 1–5; and Inj cytosine arabinoside 100 mg/m2
IV infusion 12 hourly days 1–5 and oral prednisolone 60
mg daily day 1–5 gradually to be tapered off in next two
weeks. He was also given intrathecal Inj methotrexate 12.5
mg, on day 1 of second induction. The aforementioned
chemotherapy regimen was repeated 4 weeks after the end
of the cycle, when hematopoeitic recovery was adequate
and the patient was stable. On 28th day of the intensifica-
tion, the patient bone marrow was done which showed
normal maturation of erythroid and myeloid series with
less than 5% blasts, and normal number of megakaryo-
cytes. The patient is scheduled for evaluation at Armed
Forces Bone Marrow Transplant Centre, Rawalpindi, Paki-
stan for stem cell transplantation from matched sibling
donor.
Discussion and Evaluation
The eosinophil count in a normal adult ranges from 0.02–
0.5 × 109/l (20–500/μl) [7]. Eosinophilia is classified as
mild (0.5–1.5 109/l), moderate (1.5–5 × 109/l) and severe
[8] when the eosinophil count is more than 5 × 109/l.
Although, the patient presented with severe eosinophilia
(34.5 × 109/l), there was no organ involvement, as shown
by normal ECG, echocardiography, chest X-Ray, and no
evidence of nervous system dysfunction or skin rash.
Different causes of eosinophilia, as shown in table 1, were
excluded based upon clinical evaluation and investiga-
tions of the patient. In Pakistan, infestation with Ascaris
lumbricoides, Ancylostoma duodenale, Necator americanus
and  Echinococcus  are common causes of eosinophilia.
However, there were no ova detected on stool examina-
tion and ultrasound of abdomen did not show any abnor-
mality. This patient, diagnosed as acute lymphoblastic
leukaemia, had unremarkable clinical presentation at
onset, with vague symptoms and absence of fever or lym-
Cytogenetics of the patient's bone marrow showing  45,XY,t(7;12)(q22;p13),-9 (20 cells were counted; 15 cells  showed 45 chromosomes, while 5 cells showed 46 chromo- somes) Figure 3
Cytogenetics of the patient's bone marrow showing 
45,XY,t(7;12)(q22;p13),-9 (20 cells were counted; 15 
cells showed 45 chromosomes, while 5 cells showed 
46 chromosomes).Journal of Hematology & Oncology 2009, 2:26 http://www.jhoonline.org/content/2/1/26
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phadenopathy. His complete blood counts revealed
marked eosinophilia, and interestingly absence of blasts
in the peripheral blood film. The bone marrow biopsy of
this patient showed presence of 40% blasts, which stained
negative with Sudan Black B, and were of common precur-
sor B-cell origin on flow cytometric analysis.
A variant of acute myelomonocytic leukaemia (AML-M4
Eo) [9] is associated with presence of increased number of
abnormal eosinophil precursors in the bone marrow.
Such patients usually have blasts in peripheral blood film
and a characteristic cytogenetic abnormality of inversion
of chromosome 16. Wynn et al [10] described B-cell line-
age acute lymphoblastic leukaemia in a 5 year old girl,
with peripheral hypereosinophilia, absence of blasts in
peripheral blood film and hyperdiploid blast cell popula-
tion with 5q deletion. Hypereosinophilia has also been
reported in a 4 year old boy who had granular acute lym-
phoblastic leukaemia with a normal karyotype [11]. One
case of acute lymphoblastic leukaemia with peripheral
hypereosinophilia was found to have 9p21 deletion [12],
on cytogenetic analysis. As discussed earlier, a common
cytogenetic abnormality detected in most cases of precur-
sor B acute lymphoblastic leukaemia with hypereosi-
nophilia is t(5;14), which disappears during remission
and reappears in relapse [13,14]. In the latter transloca-
tion, eosinophilia was secondary to overproduction of
interleukin-3 by the blasts, due to activation of inter-
leukin-3 gene on chromosome 5 after its translocation
adjacent to the immunoglobulin heavy chain gene on
chromosome 14 [5].
Eosinophilia may antedate the development of acute lym-
phoblastic leukemia by several months to 2 years, and the
patients may present with urticarial lesions and other
non-haematological features of hypereosnophilic syn-
drome (hepatosplenomegaly, cardiac lesions, CNS
involvement) during this period [15,16]. Hypereosi-
nophilia was present in our patient at the time of diagno-
sis of his disease, and was associated with a unique
cytogenetic abnormality of t(7;12)(q22;p13),-9, present
in majority of the metaphases. To the best of our knowl-
edge, the latter translocation has not been reported earlier
in adult B lymphoblastic leukemia/lymphoma. The
t(7;12)(q22;p13) previously reported in infant leukemia
[17], did not occur as a sole abnormality, and was accom-
panied by deletion of 7(q22q36). Two rare recurrent
translocations {t(7;12)(q36;p13) and t(7;12)(q32;p13)}
have been identified in 5/125 children, less than 18
months of age, and who were suffering from acute mye-
Table 1: Differential diagnosis of eosinophilia
Parasitic Infestations:
Ankylostoma duodenale
Necator americanus
Toxoplasma gondii
Strongyloides stercoralis
Ascaris lumbricoides
Hydatid disease
Allergic diseases
Bronchial asthma
Urticaria
Allergic rhinitis
Atopic dermatitis
Haematological malignancies
Hodgkin lymphoma
Chronic myeloid leukemia
Acute myeloid leukemia with inv (16) or t(16;16)
B lymphoblastic leukemia/lymphoma with t(5;14); IL3-IGH
Chronic eosinophilic leukemia
Myeloid & lymphoid neoplasms with eosinophilia and PDGFRA, PDGFRB and FGFR1
abnormalities
Connective tissue disorders
Rheumatoid arthritis
Serum sickness
Scleroderma
Others
Loeffler syndrome
Graft versus host diseaseJournal of Hematology & Oncology 2009, 2:26 http://www.jhoonline.org/content/2/1/26
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loid leukemia [18]. Involvement (deletions or transloca-
tions) of chromosome 7, especially in the region 7q22,
predominantly occurs in myelodysplastic syndrome [19]
and myeloid leukemias [20]. Translocation and deletion
of a segment of chromosome 7 (7q22 or 7q32-q35), or
loss of chromosome 7 may lead to inactivation (position
effect) of tumour suppressor gene(s) or their dysfunction
(at the breakpoint region), leading to transformation to
myeloid leukemias [20].
The other chromosomal gene affected in this case is
12p13. More than forty translocations involving 12p13,
or the ETV6 gene, and different partner chromosomes
have been described in various haematopoeitic malignan-
cies. t(5;12)(q31;p13) is a recurrent mutation which has
been reported in refractory anaemia with excess blasts
(RAEBt) with basophilia, acute myeloid leukemia with
eosinophilia and acute eosinophilic leukemia [21]. Chro-
mosomal abnormality affecting 12p13 and associated
with severe eosinophilia, has also been described in Phil-
adelphia negative myeloproliferative disorder, eosi-
nophilic leukemia and acute lymphoblastic leukemia
[22]. Similarly, a chimeric gene ETV6/ACS2 due to
t(9;12)(q22;p13) has been reported in myelodysplastic
syndrome associated with eosinophilia [23]. The ETV6
gene codes for a transcription activator, and has a span of
240 kb with eight exons [24,25]. Different segments of the
ETV6 gene act as fusion partners with other genes affected
in various translocations, and can result in the production
of a fusion protein having a ligand-independent tyrosine
kinase activity [26]. In our case, the events responsible for
leukemogenesis may be related to hypodiploidy, loss of
suppressor gene at 7q22, or activation of a proto-onco-
gene after translocation of 7q22 to 12p13 (ETV6 gene).
Hypodiploidy (loss of chromosome 9) is likely responsi-
ble for poor response to chemotherapy and adverse prog-
nosis, while eosinophilia seen in this case is most likely
secondary to t(7;12). The patient was categorized in the
poor risk category because of late remission (>6 weeks
after induction therapy). He is thus planned to be referred
for bone marrow transplantation from matched sibling
with a curative intent.
Conclusion
Marked increase of eosinophils in the blood and bone
marrow can occur in precursor B-acute lymphoblastic
leukemia, as a result of different cytogenetic abnormali-
ties. In majority of the cases there is absence of blasts in
the peripheral blood film. Adult B lymphoblastic leuke-
mia/lymphoma with hypodiploidy and severe eosi-
nophilia in blood and bone marrow, having cytogenetic
abnormality t(7;12)(q22;p13),-9, is a distinct entity with
poor response to chemotherapy, and a bad prognosis.
Individuals with this disease should be selected for bone
marrow transplantation from matched sibling/unrelated
donor, once remission is achieved, for best chances of dis-
ease free survival.
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